News
DXCM
65.49
+0.37%
0.24
How New CGM Lawsuits And Dexcom Academy At DexCom (DXCM) Have Changed Its Investment Story
Simply Wall St · 2h ago
DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
PR Newswire · 1d ago
Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
PR Newswire · 1d ago
DexCom Faces Class Action Lawsuit Over Alleged Securities Fraud
Reuters · 2d ago
Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds
Reuters · 2d ago
January 2026 Options Now Available For DexCom (DXCM)
NASDAQ · 3d ago
DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM
PR Newswire · 3d ago
LISTENING TO HEALTHCARE PROFESSIONALS: DEXCOM LAUNCHES NEW EDUCATION OFFERING, DEXCOM ACADEMY
Reuters · 3d ago
DexCom Inc. Faces Securities Fraud Class Action Lawsuit
Reuters · 3d ago
Is DexCom Stock Underperforming the S&P 500?
Barchart · 4d ago
Stocks Settle Higher on Strength in Chip Makers and Boeing
NASDAQ · 4d ago
DexCom Raised to Overweight From Equal-Weight by Morgan Stanley
Dow Jones · 5d ago
DexCom Price Target Raised to $75.00/Share From $63.00 by Morgan Stanley
Dow Jones · 5d ago
Morgan Stanley Upgrades DexCom to Overweight, Raises Price Target to $75
Benzinga · 5d ago
DexCom Stock Upgraded. How the Glucose Monitor Maker Is 'Turning a Corner.'
Barron‘s · 5d ago
DexCom upgraded at Morgan Stanley on sorting out operational issues
Seeking Alpha · 5d ago
Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
TipRanks · 5d ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom Lawsuit - DXCM
PR Newswire · 5d ago
Dexcom (DXCM) Gets a Buy from Piper Sandler
TipRanks · 5d ago
DexCom upgraded to Overweight at Morgan Stanley with company turning corner
TipRanks · 5d ago
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.